Loading
A registry that follows about 14,600 people who paid for or were offered Galleri in ordinary US clinics, to see how the test performs outside a trial.
REFLECTION (NCT05205967) is an observational study sponsored by GRAIL, Inc. Its primary outcome is signal detection and cancer detection within and across sites among people who opted to have Galleri.
The registry record, read on 29 October 2026, gives its status as active, not recruiting, with 14,633 participants enrolled, a start on 23 August 2021 and primary completion on 30 September 2025.
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/